WEE1 and autosomal dominant polycystic kidney disease: In summary, in silico modelling and pharmacological and biochemical data support the notion that the primary effects of mebendazole in ADPKD are likely driven via binding to the CBS of β tubulin, inhibition of microtubule polymerisation, and disruption of downstream microtubule dynamics, with a possible contribution via the inhibition of select protein kinase targets.